Physician profile
Claire E Sullivan
NPI 1558688580
$2,294.34
in general payments reported to CMS, 2019-2025
28 companies · $336 in 2025
The $336 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $246 · 2021: $207 · 2022: $279 · 2023: $392 · 2024: $506 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,233.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $454.99 | 2020-2025 | |
| Amgen INC. | $375.96 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $271.75 | 2021-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $161.55 | 2019-2025 | Farxiga, Bevespi Aerosphere |
| Novo Nordisk INC | $124.24 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $123.24 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $117.41 | 2019 | |
| Esperion Therapeutics, INC. | $77.30 | 2021-2025 | Nexletol |
| Pfizer INC. | $76.08 | 2023-2025 | |
| Amarin Pharma, INC. | $61.48 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $57.75 | 2024 | Arcalyst |
| Lantheus Medical Imaging, INC. | $50.51 | 2024-2025 | |
| Scpharmaceuticals INC. | $39.74 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $35.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.48 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $23.69 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $23.58 | 2023 | Arcalyst |
| Ionis Pharmaceuticals, INC. | $20.18 | 2025 | Tryngolza |
| Zoll Circulation INC | $20.00 | 2022 | |
| Boston Scientific Corporation | $19.99 | 2025 | Watchman Flx |
| Abbott Laboratories | $19.43 | 2023 | Mitraclip |
| Bracco Diagnostics INC. | $18.92 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.92 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.95 | 2019 | |
| Merck Sharp & Dohme LLC | $16.88 | 2023 | Verquvo |
| Chiesi USA, INC. | $16.50 | 2025 | Juxtapid |
| Genzyme Corporation | $14.95 | 2024 | |
| Aroa Biosurgery Incorporated | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.